SR-717 |
Catalog No.GC61293
One-Click Copy Product Info
|
SR-717 is a non-nucleotide STING agonist. SR-717 activates STING in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cells (EC50=2.1μM, 2.2μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2375421-09-1
Sample solution is provided at 25 µL, 10mM.
SR-717 is a non-nucleotide STING agonist. SR-717 activates STING in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cells (EC50=2.1μM, 2.2μM). SR-717 acts as a cGAMP mimetic to induce the closed conformation of STING protein. SR-717 thereby activates downstream phosphorylation of TBK1, IRF3 and STAT3 and promotes IFN-β expression. SR-717 promotes infiltration and activation of immune cells such as CD8+ T cells and NK cells, thereby inhibiting tumor growth. SR-717 can be used for cancer and inflammation/immunity related research[1-4].
In vitro, SR-717 (10μM) treatment of Caski and HeLa cervical cancer cells for 6h reduced HPV16/18 E7 oncoprotein levels and inhibited cell proliferation and colony formation[5]. SR-717 (10μM) treatment of DC2.4 cells for 24h upregulated p-TBK1 and p-IRF3 expression, promoted IFN-β secretion, and upregulated CD80 and CD86 expression to promote dendritic cell maturation[6]. SR-717 (20μM) treatment of MODE-K cells for 12h increased cell viability, inhibited apoptosis, and upregulated expression of STING, p-TBK1, p-p65, STAT3, and p-STAT3[7].
In vivo, intratumoral injection of SR-717 (30mg/kg) into A/J mice and C57BL/6 mice bearing Neuro-2A neuroblastoma cells and CT-2A glioblastoma cells every 3 days for 3 cycles significantly inhibited tumor growth of neuroblastoma and glioblastoma[8]. In neonatal mice at postnatal day 5, after induction of germinal matrix hemorrhage, a single intraperitoneal injection of SR-717 (30mg/kg) was administered immediately. SR-717 increased the number of microglia and proinflammatory cytokine levels in the perilesional area and aggravated the decrease of tight junction proteins ZO-1 and occludin[9]. In C57BL/6J mice with femoral fracture, daily intraperitoneal injection of SR-717 (30mg/kg) for 1 week promoted fracture healing, manifested as increased bone structural parameters such as bone tissue volume, bone volume fraction, and bone mineral density, and increased cartilage formation[10].
References:
[1] Chin EN, Yu C, Vartabedian VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020 Aug 21;369(6506):993-999.
[2] Wang J, Geng T, Yao X, et al. GDF15 attenuates Parkinson's disease progression via suppressing the activation of cGAS-STING pathway. Molecular and Cellular Biochemistry. 2025;480:4449-4466.
[3] Fu H, Guo X, Fang F, et al. STING pathway activation with cisplatin polyprodrug nanoparticles for chemo-immunotherapy in ovarian cancer. J Control Release. 2025 May 10;381:113565.
[4] Caldwell SE, Janosko CP, Deiters A. Development of a light-activated STING agonist. Org Biomol Chem. 2024 Jan 3;22(2):302-308.
[5] Huang X, Huo L, Xiao B, et al. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer. Cell Death Differ. 2024;31(1):78-89.
[6] Miao Z, Song X, Xu A, et al. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers. Pharmaceutics. 2024 Sep;16(9):1216.
[7] Fang D, Duan W, Zhai X, et al. SR-717, a Non-Nucleotide STING Agonist, Displayed Anti-Radiation Activity in a IL-6 Dependent Manner. The FASEB Journal. 2025;39:e70644.
[8] Lv Z, Wang T, Fan R, et al. Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression. Cancer Biol Med. 2026;23:133-153.
[9] Wang Y, Yin X, Zhang X, et al. Inhibition of cGAS reduces brain injury and facilitates neurological recovery via the STING-mediated signaling pathway after germinal matrix hemorrhage in neonatal mice. J Integr Neurosci. 2025;24(8):39286.
[10] Zheng M, Zhao L, Nian S, et al. cGAS-STING pathway mediation in osteoclast function and bone fracture healing. Front Immunol. 2026;17:1789655.
| Cell experiment [1]: | |
|
Cell lines |
DC2.4 cells (mouse dendritic cell line), RAW264.7 cells (mouse macrophage cell line) |
|
Preparation Method |
DC2.4 cells were maintained in RPMI 1640 medium supplemented with 10% FBS at 37°C, 5% CO2. Cells were treated with SR-717 at 10μM for 24 hours, followed by western blot analysis of p-TBK1 and p-IRF3, ELISA for IFN-β, and flow cytometry for CD80 and CD86 expression. RAW264.7 cells were polarized to M2 phenotype and then treated with SR-717 at 10μM for 24 hours, followed by flow cytometry for CD206 and CD86 expression. |
|
Reaction Conditions |
10μM; 24h |
|
Applications |
SR-717 increased phosphorylation of TBK1 and IRF3. SR-717 elevated IFN-β production. SR-717 decreased CD206 expression and increased CD86 expression on macrophages. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J mice |
|
Preparation Method |
6-8-week-old male C57BL/6J mice were subjected to femoral fracture surgery. From the day after surgery, mice were intraperitoneally administered SR-717 at 30mg/kg daily for one week, followed by micro-CT scanning at 2 and 4 weeks post-surgery, and safranin O-fast green staining and TRAP staining of femoral specimens at 14 days post-fracture for tissue analysis. |
|
Dosage form |
30mg/kg; i.p.; daily for one week |
|
Applications |
SR-717 increased bone tissue volume, bone volume fraction and bone mineral density. SR-717 increased STING protein expression in callus tissue. SR-717 increased cartilage area. SR-717 increased TRAP-positive osteoclast number on bone surface. |
References: [1] Miao Z, Song X, Xu A, et al. Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers. Pharmaceutics. 2024 Sep;16(9):1216. [2] Zheng M, Zhao L, Nian S, et al. cGAS-STING pathway mediation in osteoclast function and bone fracture healing. Front Immunol. 2026;17:1789655. | |
| Cas No. | 2375421-09-1 | SDF | |
| Canonical SMILES | O=C(O[Li])C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O | ||
| Formula | C15H8F2LiN5O3 | M.Wt | 351.19 |
| Solubility | DMSO: 14.29 mg/mL (40.69 mM); Water: < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8475 mL | 14.2373 mL | 28.4746 mL |
| 5 mM | 569.5 μL | 2.8475 mL | 5.6949 mL |
| 10 mM | 284.7 μL | 1.4237 mL | 2.8475 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)